Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
European Heart Journal, Supplement ; 24(SUPPL C):C12, 2022.
Article in English | EMBASE | ID: covidwho-1915555

ABSTRACT

The prevalence of heart failure in the population and the COVID pandemic have rendered increasingly necessary the integration of remote monitoring with cardiology teleconsultation. A patient with dilated cardimiopathy was subjected to ICD implantation (Boston Scientific Perciva DR) with remote monitoring (LatitudeTM). One month after implant, remote monitoring recorded an increase in the HeartLogicTM heart failure index, a decrease of right ventricular and atrial sensing, contextually to fluctuations of the impedance values of the two leads (Fig. 1). The patient reported having performed shoulder's rehabilitation therapy with probable manipulation of the ICD pocket. Chest X-ray showed dislocation of both leads with distal end of right atrial catheter in superior vena cava and distal end of right ventricular catheter in right atrium (Fig. 2A) and kinking of proximal segments (Fig. 2B), a picture compatible with diagnosis of Twiddler's syndrome. Implant revision confirmed lead kinking in the subcutaneous pocket (Fig. 3A). The atrial catheter, given the amount of tissue deposited at its distal end (Fig.3B) which prevented its active fixation, was replaced. Following discharge, an increase in the HeartLogicTM Heart Failure Index was detected. The outpatient visit showed the presence of pleural effusion and medical therapy was therefore optimized. In order to avoid frequent ambulatory visits to the patient, a cardiology teleconsultation was planned, which enabled to verify the clinical benefit of therapy's variation. Remote device monitoring confirmed HeartLogicTM Heart Failure Index normalization. In conclusion, the integration of remote monitoring with cardiology teleconsultation, enables to timely detect device malfunctions and prevent episodes of heart failure, avoiding further hospitalizations. This integration is even more useful and necessary in geographically disadvantaged areas, strengthening the link between the territory and the hospital, improving patients compliance and therapeutic adherence and thus allowing a progressive improvement of the symptoms and quality of life of heart failure patients.

2.
Biochimica Clinica ; 45(SUPPL 2):S21, 2022.
Article in English | EMBASE | ID: covidwho-1733100

ABSTRACT

Background and Aim: Salivary SARS-CoV-2 Ab determination could be suitable for monitoring the viral spread and vaccination efficacy, especially in pediatric patients. We investigated N/S1-RBD IgG antibody levels in salivary samples of infectious-naïve vaccinated subjects and of COVID-19 patients, further comparing levels with serum anti-SARS-CoV-2 S-RBD IgG. Methods: A total of 72 subjects were enrolled at the Padova University Hospital: 36 COVID-19 patients and 36 health care workers (HCW), who underwent a complete vaccination campaign with BNT162b2 (BioNTech/Pfizer). All collected a salivary sample, using Salivette (Sarstedt, Nümbrecht Germany). For 9 HCW, salivary samples were collected at three different times within the same day (before breakfast, at 10 am, and after lunch). A serum sample was also collected for all individuals. Time post symptoms onset or time from the first vaccine were also recorded. Salivary COVID-19 N/S1 RBD (sal-IgG) ELISA (RayBiotech, GA, USA) and anti-SARS-CoV-2 S-RBD IgG Ab (ser-IgG) (Snibe Diagnostics, Shenzhen, China) were used for determining IgG Ab. Results: Subjects' mean age (±sd) was 35.8±18.2 yrs. Age significantly differed (p<0.001) from COVID-19 patients [29.7±17.3 yrs] and HCW [47.1±12.9 yrs]. Positive sal-IgG were found in 70/72 (97.2%) samples;in sera, 71/72 (98.6%) samples were positive to ser-IgG. The sal-IgG median levels differed from COVID-19 to vaccinated HCW, being in salivary samples 0.21 kAU/L and 0.8 kAU/L (p =0.030), respectively;median levels for ser-IgG in COVID-19 and vaccinated HCW were 135 kBAU/L and 940 kBAU/L, respectively (p<0.001). Salivary IgG levels were not influenced by time post-symptom onset or time post-vaccination, both on vaccinated HCW (rho= -0.147, p=0.402) and COVID-19 subjects (rho=0.0267, p=0.986). Ser-IgG levels was not influenced by the time post-symptom onset for COVID-19 subjects (rho=0.102, p=0.419), while a strong significant correlation was found with time post-vaccination in HCW (rho=-0.6292, p<0.001). Sal-IgG levels were notinfluenced by the daytime of collection (rho=0.148, p=0.373). Passing-Bablok regressions showed that sar- IgG and ser-IgG comparability was assessable only when ser-IgG values were divided by 1000, being slope and intercept 0.068 (95%CI: 0.069-0.341) and 0.221 (95%CI:- 0.097 to 0.786), respectively. Conclusions: Salivary IgG is efficiently detectable both in COVID-19 and in vaccinated individuals and analyses appeared to be not influenced by the daytime of collection. The analyses performed showed that, overall, sal-IgG were lower than ser-IgG, and thus comparability with serum levels needs to be better explored.

SELECTION OF CITATIONS
SEARCH DETAIL